Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate

Behdani, Fatemeh; Roudbaraki, Seyede Narjes; Saberi‐Karimian, Maryam; Tayefi, Maryam; Hebrani, Paria; Almasi‐Hashiani, Amir; Vahabi-Amlashi, Sadegh; Ferns, Gordon A.; Ghayour‐Mobarhan, Majid

doi:10.1016/j.psychres.2017.12.028

Cited by 10 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of ~70 randomized, controlled trials to date that have examined adjunctive anti-inflammatory drugs on psychosis symptoms or cognition in schizophrenia, 5,63 22 publications 64–85 have investigated and reported the influence of the interventions on peripheral measures of inflammation. Eight 65–72 of these identified changes in these measures corresponding to clinical or cognitive outcome measures of response.…”

Section: Therapeutic Implications: Anti-inflammation Interventions An...mentioning

confidence: 99%

Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies

Bishop

Zhang²,

Lizano³

2022

Harv Rev Psychiatry

View full text Add to dashboard Cite

Dysregulation of immunological and inflammatory processes is frequently observed in psychotic disorders. Numerous studies have examined the complex components of innate and adaptive immune processes in schizophrenia and related psychoses. Elevated inflammation in these conditions is related to neurobiological phenotypes and associated with both genetics and environmental exposures. Recent studies have utilized multivariate cytokine approaches to identify what appears to be a subset of individuals with elevated inflammation. The degree to which these findings represent a general process of dysregulated inflammation or whether there are more refined subtypes remains unclear. Brain-imaging studies have attempted to establish the link between peripheral inflammation and gray matter disruption, white matter abnormalities, and neuropsychological phenotypes. However, the interplay between peripheral inflammation and neuroinflammation, as well as the consequences of this interplay, in the context of psychosis remains unclear and requires further investigation. This Perspectives article reviews the following elements of immune dysregulation and its clinical and therapeutic implications: (1) evidence supporting inflammation and immune dysregulation in schizophrenia and related psychoses; (2) recent advances in approaches to characterizing subgroups of patients with elevated inflammation; (3) relationships between peripheral inflammation and brain-imaging indicators of neuroinflammation; (4) convergence of large-scale genetic findings and peripheral inflammation findings; and (5) therapeutic implications: anti-inflammation interventions leveraging genetic findings for drug discovery and repurposing. We offer perspectives and examples of how multiomics technologies may be useful for constructing and studying immunogenetic signatures. Advancing research in this area will facilitate biomarker discovery, disease subtyping, and the development of etiological treatments for immune dysregulation in psychosis.

show abstract

Section: Therapeutic Implications: Anti-inflammation Interventions An...mentioning

confidence: 99%

Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies

Bishop

Zhang²,

Lizano³

2022

Harv Rev Psychiatry

View full text Add to dashboard Cite

show abstract

“…All eligible studies are summarized in Supplemental Material 1. We identified 20 RCTs with primary results that met our prespecified criteria for inclusion in this meta-analysis, including two studies of an ultra-high-risk population (Amminger et al, 2010; McGorry et al, 2017), three studies of patients first episode psychosis (Berger et al, 2007; Emsley et al, 2014; Pawelczyk et al, 2016) and 15 studies of schizophrenia patients (Behdani et al, 2018; Bentsen et al, 2013; Bošković et al, 2016; Emsley et al, 2002, 2006; Faghihi et al, 2012; Fenton et al, 2001; Jamilian et al, 2014; Manteghiy et al, 2008; Peet and Horrobin, 2002; Peet et al, 2001; Qiao et al, 2018; Robinson et al, 2019; Xu et al, 2019).…”

Section: Resultsmentioning

confidence: 99%

Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials

Goh

Chen

et al. 2021

J Psychopharmacol

View full text Add to dashboard Cite

Background: Several monotherapy and augmentation strategies have been introduced to improve the treatment of schizophrenia. The benefits of omega-3 polyunsaturated fatty acids in patients with mental disorders is becoming increasingly acknowledged. However, its role in the treatment of schizophrenia raises complex considerations about which there has been little consensus. The aim of this study was to synthesize the findings of randomized controlled trials that were conducted to determine the efficacy and safety of omega-3 polyunsaturated fatty acids in patients with schizophrenia. Methods: The MEDLINE, Embase, Cochrane, Scopus, and Web of Science databases were searched for relevant literature. The primary outcome was changes in psychopathology and the secondary outcomes were changes in metabolic parameters and safety profiles. Results: Twenty double-blind randomized controlled trials in 1494 patients were included. Omega-3 polyunsaturated fatty acids augmentation was associated with significantly improved psychopathology in patients with schizophrenia, particularly general psychopathology and positive symptoms but not negative symptoms. Patients who were severely ill and received omega-3 polyunsaturated fatty acids containing eicosapentaenoic acid >1 g/d showed significant improvement. A favorable effect of omega-3 polyunsaturated fatty acids supplements on serum triglycerides was also demonstrated. Omega-3 polyunsaturated fatty acids are well-tolerated and safe in patients with schizophrenia. Conclusions: These findings tentatively support the use of omega-3 polyunsaturated fatty acids as a potential augmentation strategy in schizophrenia. Further research in larger samples is warranted to clarify the optimal dosage and the correct proportions of omega-3 polyunsaturated fatty acids to administer, together with elucidation of the underlying mechanisms.

show abstract

“…after taking n-3 PUFA supplements for 4 weeks. 20 In addition, n-3 PUFA supplementation considerably reduced inflammatory (tumor necrosis factor-α) and metabolic (triglyceride) levels in patients with schizophrenia, which had been found to differ during the baseline assessment performed before therapy, according to the Chinese study. 21 For every selected study, the Newcastle-Ottawa scale was used to assess the risk of bias.…”

Section: Analysis Of the Literaturementioning

confidence: 98%

“…21 However, there were minor improvements in the waist circumference in the Iranian study, a parameter linked to many diseases associated with schizophrenia, including cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus. 20 The symptoms of schizophrenia are more severe in patients with low n-3 PUFA levels than in those with high levels, 24 and these patients respond better to n-3 PUFA supplementation. Supplementation with n-3 PU-FAs is more likely to be beneficial for patients whose baseline levels of EPA and alpha-lipoic acid are greater.…”

Section: Analysis Of the Literaturementioning

confidence: 99%

Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review

Vityala,

Kanteti,

Vityala

et al. 2024

Eur J Clin Exp Med

View full text Add to dashboard Cite

Introduction and aim. In patients with schizophrenia, omega-3 (n-3) polyunsaturated fatty acids (PUFAs) treatment was found to ameliorate the cardiovascular, metabolic, and inflammatory problems caused by antipsychotic medication and even reduce the need for medication by 20%. In this study, we evaluated the potential therapeutic effects of n-3 PUFA supplementation in patients with schizophrenia. Material and methods. The PRISMA guidelines were followed in conducting this systematic review. The Embase, MEDLINE, Web of Science, and Google Scholar databases were searched electronically. The first search yielded 50 papers in total. Subse quently, 43 publications that did not meet our eligibility requirements were removed, and seven articles were selected. Analysis of the literature. The analysis showed that n-3 PUFA supplementation and the placebo group both decreased their psychotic (PANSS and GAF scales) and Calgary Depression Scale symptomatology and boosted their functional ability (GAF) when used as an adjuvant to antipsychotic medication. When administered as a monotherapy with a metabolic antioxidant, n-3 PUFA supplementation proved beneficial for treating schizophrenia. In patients with schizophrenia, n-3 PUFAs have thera peutic benefits as adjuvant treatments to medications, although not for different variables or patient groups. Conclusion. In many studies, patients with chronic schizophrenia who received n-3 PUFA supplementation showed no improvement in their clinical condition.

show abstract

Assessment of the efficacy of omega-3 fatty acids on metabolic and inflammatory parameters in patients with schizophrenia taking clozapine and sodium valproate

Cited by 10 publications

References 20 publications

Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies

Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies

Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials

Therapeutic advantages of omega-3 fatty acid supplementation in patients with schizophrenia – a systematic review

Contact Info

Product

Resources

About